Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study [0.03%]
回顾性分析IPSOS研究中NSCLC患者铂类不耐受的验证结果
Solange Peters,Christian Schulz,Martin Reck et al.
Solange Peters et al.
Introduction: The Phase III IPSOS study (NCT03191786) demonstrated that atezolizumab was associated with improved survival, stable patient-reported outcomes and a favorable safety profile vs single-agent chemotherapy in p...
The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing [0.03%]
2024年国际肺癌研究协会全球生物标志物检测调查问卷
Matthew P Smeltzer,Jennifer C King,Casey Connolly et al.
Matthew P Smeltzer et al.
Introduction: Biomarker status is vital to inform optimal care for individuals with lung cancer, yet implementation of testing has been sub-optimal due to cost, lack of quality and standards, access, awareness, and long t...
Erratum to 'Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review' [Journal of Thoracic Oncology Volume 19 Issue 7 (2024) 973-983] [0.03%]
关于“非小细胞肺癌罕见EGFR突变的系统评价”一文的勘误[J Thorac Oncol卷19期7(2024)973-983]
Maxime Borgeaud,Kaushal Parikh,Giuseppe Luigi Banna et al.
Maxime Borgeaud et al.
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer [0.03%]
肺癌分子肿瘤板国际多学科专家共识声明
Mihaela Aldea,Julia K Rotow,Maria Arcila et al.
Mihaela Aldea et al.
Context: Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the succ...
In Response [0.03%]
回应
Dongchen Xie,Wanghong Xu
Dongchen Xie
Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations [0.03%]
低剂量螺旋CT筛查导致平均风险中国人群过度诊断肺癌
Donghui Jin,Jiwei Wu,Wenqun Xing
Donghui Jin
A Response to the Letter to the Editor: "In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC" [0.03%]
对“原位检测程序性细胞死亡蛋白1和程序性死亡配体1相互作用作为非小细胞肺癌免疫检查点抑制反应的功能预测指标”的编辑来信的回复
Amanda Lindberg,Patrick Micke,Carina Strell
Amanda Lindberg
A Response to the Letter to the Editor: "Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis" [0.03%]
致编辑部的回信：“决策树与随机森林：生物数据分析中逻辑回归的非线性和非参数替代方法”
Shun Lu,Binbing Yu,Dan Jackson et al.
Shun Lu et al.
Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis [0.03%]
决策树和随机森林：生物数据分析中逻辑回归的非线性和非参数替代方法
Yoshiyasu Takefuji
Yoshiyasu Takefuji